Outcomes of First-Line vs Second-Line CDK4/6 Inhibitor Use in Patients With HR+/HER2− Metastatic Breast Cancer in the Real-World Setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting
Breast Cancer Res Treat 2024 Jun 26;[EPub Ahead of Print], G Kimmick, A Pilehvari, W You, G Bonilla, R AndersonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.